AbbVie Rides 7-Day Winning Streak, Ends Week at $189.90

AbbVie has gained for seven consecutive sessions, with a 1.3% increase to $189.90 on Friday. The stock has risen nearly 7% year-to-date, outperforming the broader market.

AbbVie Inc. (ABBV) has seen a remarkable performance in recent weeks, with the stock gaining for seven consecutive sessions. On Friday, June 7, 2025, the stock closed at $189.90, marking a 1.3% increase. This upward trend has been consistent, with the stock rising nearly 7% year-to-date, outperforming the broader market [1].

The total return for AbbVie stock over the past 12 months stands at 19.18%, and the 5-year total return is 168.90%. This indicates that $1000 invested in ABBV stock five years ago would now be worth $2,688.98, highlighting the stock's strong performance over the medium term [2].

AbbVie's performance has been driven by various factors, including positive earnings reports, strategic partnerships, and innovative product developments. The company has also been actively engaging with investors through events like the Goldman Sachs 46th Annual Global Healthcare Conference and the AbbVie Migraine Career Catalyst Award™ Contest [1].

Investors should keep an eye on AbbVie's upcoming financial reports and any new developments in the healthcare sector, as these could significantly impact the stock's performance. Additionally, the ongoing class action lawsuits against Cerevel Therapeutics Holdings, Inc. (ABBV) may have implications for the company's financial health [1].

References:
[1] PR Newswire, "AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference," June 3, 2025.
[2] FinanceCharts, "ABBV Stock / Performance / Total Return All Data A-Z," accessed June 7, 2025.